Enterra Medical

Enterra Medical

Develops implantable gastric electrical stimulation therapy

Overview

Enterra Medical develops the Enterra Therapy system, a gastric electrical stimulation implant for adults with drug-refractory gastroparesis. The system includes a small implant in the lower abdomen and two leads placed into the stomach wall; it sends mild electrical pulses to stomach muscles and nerves and can be adjusted by a physician using an external programmer, with the option to turn off or remove the device. Its approach centers on this specific therapy with ongoing improvements (such as the Enterra II MR Conditional system and the Enterra ReliaStim lead) and collaboration with Medtronic as an operational partner. The goal is to provide a safe, adjustable, and reversible treatment that relieves chronic nausea and vomiting and improves quality of life for patients when other treatments have failed.

About Enterra Medical

Simplify's Rating
Why Enterra Medical is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Healthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Minneapolis, Minnesota

Founded

2022

Get referred to Enterra Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • NAVIGATE enrolled 148 patients across U.S., Europe, and Britain by August 2026.
  • Enterra ReliaStim launched January 2026, signaling active product iteration and surgeon workflow gains.
  • Expanded MRI labeling in 2023 directly removes a common reason physicians avoid implanted devices.

What critics are saying

  • The FDA still says Enterra effectiveness for gastroparesis has not been demonstrated.
  • NAVIGATE, started June 2025, must prove chronic-nausea efficacy before label expansion.
  • If payer coverage stalls, Enterra remains a niche implant business with limited procedure volume.

What makes Enterra Medical unique

  • Enterra Medical owns the only FDA HDE gastroparesis GES franchise since 2000.
  • January 2026 Enterra ReliaStim added proprietary lead placement hardware to Enterra Therapy.
  • Enterra II MR Conditional approval expanded MRI access, easing a major implant barrier.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Recently Posted Jobs

Sign up to get curated job recommendations

Enterra Medical is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →